Who are Zoledronic acid i.v. 5 years's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ibandronate [Bonviva/Boniva], Ibandronate (SB743830HD), Marketed Cavity Protection Toothpaste, SnF, Risedronate (HMR4003), Hormone Replacement Therapy and Etidronate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zoledronic-acid-i-v-5-years.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Zoledronic acid i.v. 5 years — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zoledronic acid i.v. 5 years (Zoledronic acid i.v. 5 years) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Oncology, Bone Diseases.

phase 3 Bisphosphonate Hydroxyapatite Oncology, Bone Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Zoledronic acid i.v. 5 years (Zoledronic acid i.v. 5 years) — Ludwig-Maximilians - University of Munich. Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Zoledronic acid i.v. 5 years TARGET	Zoledronic acid i.v. 5 years	Ludwig-Maximilians - University of Munich	phase 3	Bisphosphonate	Hydroxyapatite
ibandronate [Bonviva/Boniva]	ibandronate [Bonviva/Boniva]	Hoffmann-La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase (indirect); hydroxyapatite in bone (binding site)
Ibandronate (SB743830HD)	Ibandronate (SB743830HD)	GlaxoSmithKline	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Marketed Cavity Protection Toothpaste	Marketed Cavity Protection Toothpaste	Procter and Gamble	marketed	Fluoride-based remineralizing agent	Tooth enamel hydroxyapatite; oral bacterial metabolism
SnF	SnF	GlaxoSmithKline	marketed	Topical fluoride agent	Tooth enamel (hydroxyapatite); oral bacteria
Risedronate (HMR4003)	Risedronate (HMR4003)	Sanofi	marketed	Bisphosphonate	Hydroxyapatite (bone mineral); osteoclast farnesyl pyrophosphate synthase
Hormone Replacement Therapy and Etidronate	Hormone Replacement Therapy and Etidronate	British Thoracic Society	marketed	Hormone replacement therapy combined with bisphosphonate	Estrogen receptor (HRT component); bone hydroxyapatite and osteoclast function (etidronate component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

· 2 drugs in this class
Amgen · 2 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Sanofi · 2 drugs in this class
Ludwig-Maximilians - University of Munich · 2 drugs in this class
Chinese University of Hong Kong · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Aarhus University Hospital · 1 drug in this class
Eisai Inc. · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zoledronic acid i.v. 5 years — Competitive Intelligence Brief. https://druglandscape.com/ci/zoledronic-acid-i-v-5-years. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab